hrp0084p1-82 | Growth Hormone | ESPE2015

Assessment of Primary Cancers in Growth Hormone–Treated Paediatric Patients Compared with General Population Registries: An Epidemiological Analysis of a Large, Multinational, Prospective Observational Study

Child Christopher , Zimmermann Alan , Jia Nan , Robison Leslie , Bramswig Jurgen , Blum Werner

Background: Concern remains regarding the potential influence of growth hormone (GH) treatment on neoplasia because of the general growth-inducing effect of GH and associations between high serum IGF1 concentrations and certain cancers in adulthood. Many studies that evaluated risk for primary cancer in GH-treated patients without previous malignancy found no increased rates of primary neoplasia. A higher risk for colorectal cancer was observed in a single-country cohort treat...

hrp0084p3-972 | GH & IGF | ESPE2015

Time Trends in Baseline Characteristics (2006–2014) in Short Children with Growth Hormone Deficiency (GHD), Born Small for Gestational Age (SGA) and with Ullrich-Turner Syndrome (TS) Enrolled in Nordinet® International Outcomes Study (IOS) in Germany and Czech Republic

Dorr Helmuth Gunther , Bramswig Jurgen , Meckes-Ferber Stefanie , Pournara Effie , Pedersen Birgitte Tonnes , Snajderova Marta

Background: Early diagnosis of growth disorders and initiation of GH therapy at a younger age improves clinical outcomes.Aims and objectives: To analyse time trends in baseline parameters at GH treatment start (2006 – 2014) in short children with GHD, SGA and TS from Germany and Czech Republic enrolled in NordiNet® IOS (NCT00960128).Method: Baseline data (chronological age, height, weight, BMI, GH dose) from pa...